NASDAQ:COGT

Cogent Biosciences Q1 2025 Earnings Results & Report

Cogent Biosciences logo
$27.85 +0.41 (+1.49%)
Closing price 04:00 PM Eastern
Extended Trading
$28.00 +0.15 (+0.54%)
As of 05:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cogent Biosciences beat analyst earnings expectations in its Q1 2025 results, released May 6, 2025. The company reported EPS of -$0.52 versus the -$0.56 consensus estimate.

Earnings Announcement Details

Quarter
Q1 2025
Report Date
Time
Before Market Opens
Conference Call
8:00 AM ET

Cogent Biosciences EPS Results

Actual EPS
-$0.52
Consensus EPS
-$0.56
Beat/Miss
Beat by +$0.04
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 8 quarters

Cogent Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Cogent Biosciences Q1 2025 Earnings FAQ

Cogent Biosciences (NASDAQ:COGT) reported earnings of -$0.52 per share for Q1 2025, beating the consensus estimate of -$0.56. The report was announced on Tuesday, May 6, 2025.

Cogent Biosciences Earnings Headlines

HC Wainwright Cuts Earnings Estimates for Cogent Biosciences
Last call for your free 0DTE report
The 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, protect it. This report normally sells for $29.97, but it's available as a free download for a limited time.tc pixel
See More Cogent Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cogent Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cogent Biosciences and other key companies, straight to your email.

About Cogent Biosciences

Cogent Biosciences (NASDAQ:COGT) is a clinical-stage biotechnology company developing precision medicines for diseases driven by specific genetic mutations. Its research focuses on targeted therapies intended to address the underlying causes of these conditions.

The company’s lead investigational medicine, bezuclastinib, is a selective inhibitor of the KIT protein. Cogent has studied it in clinical programs for systemic mastocytosis and gastrointestinal stromal tumors (GIST), conditions in which abnormal KIT signaling can play a role. Bezuclastinib is investigational and has not been established as a treatment for these diseases.

Cogent took its current name in 2020 following a merger with Unum Therapeutics. The company’s activities center on developing and advancing its precision-medicine pipeline through clinical research.

View Cogent Biosciences Profile